Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.00.

A number of analysts have issued reports on the company. Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. BTIG Research restated a “buy” rating and set a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Finally, Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th.

Evolus Price Performance

NASDAQ:EOLS remained flat at $6.90 during mid-day trading on Friday. 534,868 shares of the company traded hands, compared to its average volume of 725,787. Evolus has a 52-week low of $3.86 and a 52-week high of $10.20. The firm’s fifty day simple moving average is $6.43 and its 200-day simple moving average is $5.56. The company has a market capitalization of $454.40 million, a P/E ratio of -10.30 and a beta of 1.32.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. As a group, equities analysts anticipate that Evolus will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its stake in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP purchased a new position in Evolus during the 3rd quarter worth approximately $37,000. Aquatic Capital Management LLC purchased a new position in Evolus during the 3rd quarter worth approximately $48,000. Finally, State of Wyoming acquired a new position in Evolus during the fourth quarter worth approximately $63,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.